Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12922611 | 0.80 | ALDH1A1 (0.43) | CCR2MAPTPOLBCYP3A4LMNA | |
| SCHEMBL977741 | 0.78 | KIF11 (0.49) | KIF11 | |
| SCHEMBL977528 | 0.77 | CCR2 (0.40) | CCR2KIF11POLB | |
| SCHEMBL12330754 | 0.77 | CFTR (0.39) | KIF11CA12CA9 | |
| SCHEMBL12330515 | 0.75 | CA12 (0.37) | CCR2GAAKIF11SIRT6CYP3A4 | |
| SCHEMBL977855 | 0.73 | AR (0.44) | KIF11AR | |
| SCHEMBL13302030 | 0.73 | KIF11 (0.36) | KIF11CYP3A4ARCYP1A2TSHR | |
| SCHEMBL979706 | 0.71 | ALDH1A1 (0.47) | KIF11MAPTPOLBSIRT6CYP3A4 | |
| SCHEMBL31451451 | 0.71 | ALDH1A1 (0.47) | KIF11MAPTPOLBSIRT6CYP3A4 | |
| SCHEMBL20225775 | 0.71 | GAA (0.47) | GAAMAPTPOLBCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| EP-2078712-B1 | Indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2078712-B1 | Indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | disclosed |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-09-04 | — | — | US | disclosed |
| EP-1753749-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-1753749-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8765782-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-01 | — | — | US | disclosed |
| US-8765782-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-01 | — | — | US | disclosed |
| US-20080070970-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | LANTER JAMES C | 2008-03-20 | — | — | US | disclosed |
| US-7288553-B2 | Indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| US-7288553-B2 | Indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| US-7288553-B2 | Indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| US-7282507-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | disclosed |
| US-7282507-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | disclosed |
| US-7282507-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | disclosed |
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | AR, NR5A1, FSHR | CCR2 243/4885GAA 4706/4885KIF11 3813/4885 |
| US-20140249197-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | CCR2 1037/4885GAA 4636/4885KIF11 2731/4885 |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | CCR2 1037/4885GAA 4636/4885KIF11 2731/4885 |
| US-20080070970-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | CCR2 1037/4885GAA 4636/4885KIF11 2731/4885 |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | AR, NR5A1, NR5A2 | CCR2 1041/4885GAA 4665/4885KIF11 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.